The association of haptoglobin levels and phenotype with cardiovascular disease in Type 2 diabetes: a Fenofibrate Intervention and Event Lowering in Diabetes sub-study

We evaluated the relationship of different forms or phenotypes of the blood protein, haptoglobin, and its circulating levels with the risk of developing CVD and fenofibrate benefit in patients with Type 2 diabetes, and showed that both HP phenotype and levels are important to assess CVD risk in patients with Type 2 diabetes, although fenofibrate did not modulate CVD risk via HP phenotype or level.Higher baseline HP levels were associated with higher CVD risk, especially in participants with HP 1-1 phenotype.Fenofibrate benefit on CVD did not differ by HP phenotype and baseline or change in HP levels.

Authors

Institutions

Publication Details

Journal
European Journal of Preventive Cardiology
Published
2025-09-09
DOI
https://doi.org/10.1093/eurjpc/zwaf562
Citations
1
Primary Topic
Hemoglobin structure and function
Type
article
Field-Weighted Citation Impact
1.15

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The association of haptoglobin levels and phenotype with cardiovascular disease in Type 2 diabetes: a Fenofibrate Intervention and Event Lowering in Diabetes sub-study

Rachel O’Connell, ANTHONY C. KEECH, Andrzej S. Januszewski, Habib Francis et al.
1 citations
European Journal of Preventive Cardiology
Hemoglobin structure and function
1.15
article

The association of haptoglobin levels and phenotype with cardiovascular disease in Type 2 diabetes: a Fenofibrate Intervention and Event Lowering in Diabetes sub-study

Rachel O’Connell, ANTHONY C. KEECH, Andrzej S. Januszewski, Habib Francis, Peter G. Colman, Kwok Leung Ong, James D. Best, DAVID R. SULLIVAN, Alicia J. Jenkins, Russell Scott, Abubakar Mangani, Liping Li
article en
1 citations

Abstract

We evaluated the relationship of different forms or phenotypes of the blood protein, haptoglobin, and its circulating levels with the risk of developing CVD and fenofibrate benefit in patients with Type 2 diabetes, and showed that both HP phenotype and levels are important to assess CVD risk in patients with Type 2 diabetes, although fenofibrate did not modulate CVD risk via HP phenotype or level.Higher baseline HP levels were associated with higher CVD risk, especially in participants with HP 1-1 phenotype.Fenofibrate benefit on CVD did not differ by HP phenotype and baseline or change in HP levels.

European Journal of Preventive CardiologyVol. 33(1)
The University of Sydney (AU), The Royal Melbourne Hospital (AU), Baker Heart and Diabetes Institute (AU), Nanyang Technological University (SG), Royal Prince Alfred Hospital (AU), Christchurch Hospital (NZ), Medical Research Foundation (GB)
Diabetes Australia, National Heart Foundation of Australia, Diabetesliitto, Medical Research Council, National Health and Medical Research Council, Sydney Medical School, Sydney Medical School Foundation
Openalex Percentile: Top 20%
Hemoglobin structure and function
1.15
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.